Trial Profile

A Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients With High Risks of Recurrence

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donafenib (Primary) ; Programmed cell death 1 receptor antagonists
Indications Carcinoma; Liver cancer
Focus Therapeutic Use
Acronyms CISLD-8

Most Recent Events

04 Jun 2024 Results(From June 2020 to November 2023, n=30 pts) exploring the utility of donafenib combined with anti-PD-1 antibody as adjuvant therapy for pts with high risks of recurrence , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
12 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
12 Jun 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com